Home › Research › Brain tissue and pathology
Cerebral Amyloid Angiopathy and Risk of Dementia in Patients With Cognitive Complaint
Nicolas Raposo, Matthieu Morice Morand, Thomas Genin, Marianne Lepetit, Johanna Conhoc, Vincent Bouteloup, Jean‐François Mangin, Marie Chupin et al.. Neurology, 2026-05-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Of 2,323 MEMENTO participants, 2,136 (92%) were included in this study. The mean age (SD) at baseline was 71.3 (7.9) years and 1,320 (62%) were women. Probable CAA was diagnosed in 413 (19.3%) patients using the Boston criteria V2.0, and 144 (7.0%) using the Boston criteria V1.5. During a median follow-up of 5.0 years (interquartile range 3.1-5.1), 307 participants developed dementia. Compared with controls, patients with probable CAA according to the Boston criteria V2.0 (HR 1.73, 95% CI 1.23-2.42) and V1.5 (HR 2.23, 95% CI 1.56-3.20) had increased risk of dementia. After adjusting for age, sex, baseline Mini-Mental State Examination score and hippocampal volume, patients with probable CAA per Boston criteria V1.5 but not V2.0 had an increased risk of dementia compared with controls. This association was not significant when further adjusting with APOE ε4. CAA is a common condition in outpatients with mild cognitive symptoms. Patients with probable CAA according to the Boston criteria V1.5 but not V2.0 have increased risk of dementia. Further studies are required to externally validate these findings and evaluate potential mediation effect of APOE genotype.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 307 participants. In outpatients with mild cognitive symptoms, probable CAA by Boston criteria V1.5 but not V2.0 was associated with increased risk of dementia, and this association was not significant when further adjusting for APOE ε4. Reported effect size: 19.3%; 7.0%; HR 1.73.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Raposo, N., Morand, M. M., Genin, T., Lepetit, M., Conhoc, J., Bouteloup, V., et al. (2026). Cerebral Amyloid Angiopathy and Risk of Dementia in Patients With Cognitive Complaint. Neurology. https://doi.org/10.1212/wnl.0000000000218009
Vancouver
Raposo N, Morand MM, Genin T, Lepetit M, Conhoc J, Bouteloup V, et al. Cerebral Amyloid Angiopathy and Risk of Dementia in Patients With Cognitive Complaint. Neurology. 2026. doi:10.1212/wnl.0000000000218009. PMID: 42081781.
BibTeX
@article{raposo2026-42081781,
author = {Raposo, Nicolas and Morand, Matthieu Morice and Genin, Thomas and Lepetit, Marianne and Conhoc, Johanna and Bouteloup, Vincent and Mangin, Jean‐François and Chupin, Marie and others},
title = {{Cerebral Amyloid Angiopathy and Risk of Dementia in Patients With Cognitive Complaint}},
journal = {Neurology},
year = {2026},
doi = {10.1212/wnl.0000000000218009},
pmid = {42081781},
url = {https://doi.org/10.1212/wnl.0000000000218009}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Of 2,323 MEMENTO participants, 2,136 (92%) were included in this study.
- The mean age (SD) at baseline was 71.3 (7.9) years and 1,320 (62%) were women.
- Probable CAA was diagnosed in 413 (19.3%) patients using the Boston criteria V2.0, and 144 (7.0%) using the Boston criteria V1.5.
- During a median follow-up of 5.0 years (interquartile range 3.1-5.1), 307 participants developed dementia.
- Compared with controls, patients with probable CAA according to the Boston criteria V2.0 (HR 1.73, 95% CI 1.23-2.42) and V1.5 (HR 2.23, 95% CI 1.56-3.20) had increased risk of dementia.
Why it matters
In outpatients with mild cognitive symptoms, probable CAA by Boston criteria V1.5 but not V2.0 was associated with increased risk of dementia, and this association was not significant when further adjusting for APOE ε4. The authors call for external validation, and no treatment, cure or prevention is reported.
Study details
- Study designprospective cohort
- Participants307
- Effect size19.3%; 7.0%; HR 1.73
- Evidence strengthModerate
How this study scored 63/100
Published in a leading specialty journal, and it is a prospective cohort study, followed forward from enrollment. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 60 of the 96 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A prospective cohort study, followed forward from enrollment |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 307 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 8.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author for the MEMENTO Study Group holds only 2 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 3 / 3 | Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 16 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42081781) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 60 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 60 of the 96 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Brain tissue and pathology from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.